Deals
UCB Paid $1.15B for Neurona's Single-Dose Epilepsy Cell Therapy
UCB paid up to $650m upfront, with up to $500m in future milestones, to buy Neurona Therapeutics in a deal valued at up to $1.15bn.
Deals — Page 6
M&A, fundraising, IPOs, and bankruptcies in regulated industries.
Deals
Bought Comerica. Now Fifth Third Converts 500,000 Customers by Labor Day
Fifth Third bought Comerica in February, folding in about $294 billion in assets and roughly 500,000 retail customers.
Deals
Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record
Kailera Therapeutics priced just under 40 million shares at $16 apiece Friday, pulling in $625 million on its Nasdaq debut under KLRA.
Deals
Topped $30B: Revolution Medicines Buyout Climbs on Cancer Win
Revolution Medicines had a rumored $30 billion buyout offer on the table in January.
Deals
Kailera Prices $625M IPO, Largest Biotech Since Moderna
Kailera Therapeutics priced its IPO at $625m, or $16 a share, on April 16 — at the top of its S-1 range and one of the largest biotech public offerings…
Deals
Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018
Kailera Therapeutics priced its IPO at $16 a share Friday, raising $625 million, the largest biotech public offering in recent memory, topping Moderna's…
Deals
Daiichi Sankyo Sold $1.55B Consumer Unit to Suntory
Daiichi Sankyo will sell its consumer health subsidiary to Suntory Holdings for 246.5 billion yen, about $1.55 billion, paid in tranches over three years.
Deals
Filed: Nir Zuk's Bid for $442M-Asset Liberty Bank
Nir Zuk, the Israeli billionaire who founded Palo Alto Networks, filed a Federal Reserve application Wednesday to acquire voting shares of DMG Bancshares…
Deals
OpenEvidence and Tandem Merge $13B in AI Into One Prescription Workflow
OpenEvidence and Tandem linked their platforms to automate the gap between clinical decisions and prior auth approvals.
deals
Deals
Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total
Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year's full-year total of $20.3 billion with three…
Deals
Aligos Sells China HBV Rights to Amoytop in $445M Deal
Aligos Therapeutics sold the Greater China rights to pevifoscorvir sodium to Fujian-based Amoytop for up to $445 million: $25 million upfront and $420…
Deals
Revolution Doubles Offering to $2B at $142 After Daraxonrasib Phase 3 Win
Revolution Medicines is raising $2 billion in a stock offering priced at $142 per share, up from the $1 billion it announced Monday, hours after reporting…
Deals
Revolution Medicines Prices Record Raise, Biotech's Biggest Since Pandemic
Revolution Medicines just priced a public equity raise, the largest single biotech offering since the Covid-19 pandemic.
Deals
Sold for $1.55B: Daiichi Sankyo's OTC Unit Goes to Suntory
Daiichi Sankyo sold its consumer health unit to Suntory Holdings for 246.5 billion yen, roughly $1.55 billion, in a staged transfer that kicks off this June…
Deals
Biogen Paid $5.6B for Apellis; Filing Confirms Deal Terms
Biogen paid $5.6B for Apellis, and a new SEC filing confirmed the deal details CEO Chris Viehbacher has been engineering: a company that doesn't grow on…
Deals
Bain Built $300M Beeline Medicines on 5 BMS Autoimmune Programs
Bain Capital put $300 million into Beeline Medicines at launch, licensing five autoimmune programs from Bristol Myers Squibb to build its next specialty…
Deals
Alamar Biosciences Files $159M IPO on 196% Revenue Growth
Alamar Biosciences wants $159 million from public markets, pricing 9.4 million shares at $15 to $17 apiece for a Nasdaq listing under "ALMR.
Deals
Click Therapeutics Cut More Than a Quarter of Staff After Series D
Click Therapeutics raised Series D funding, then cut more than a quarter of its workforce shortly after.
Deals
AbbVie Bought Two NaV1.8 Pain Assets from Haisco for $745M
AbbVie bought ex-China rights to two NaV1.8 sodium channel pain inhibitors from Beijing-based Haisco Pharmaceutical for up to $745 million.
Deals
Kailera Files $528.5M Nasdaq IPO to Fund Four GLP-1 Obesity Drugs
Kailera filed for a $528.5 million Nasdaq IPO, pricing 33.33 million shares at $14 to $16 each.
